A new medication provided by the NHS aims to assist individuals suffering from multiple sclerosis (MS) in improving their ability to walk. The drug fampridine, now available to thousands of patients in England, acts as a “signal booster” for nerves damaged by MS, enhancing the transmission of electrical messages to the muscles.
Previously, patients were limited to options like physiotherapy or walking aids, but now around 5,000 individuals will have access to this twice-daily pill. Ceri Smith, from the MS Society, expressed joy over the approval of fampridine for NHS use, highlighting its significance for over 120,000 MS patients in England.
MS, an incurable autoimmune condition affecting the brain and spinal cord, presents symptoms such as fatigue, dizziness, tingling sensations, muscle cramps, vision issues, and memory difficulties. Fampridine, priced at about £4,700 per patient annually, has been made more affordable through negotiations by the NHS.
According to Professor Frankie Swords, the NHS national medical director, the pill can be transformative for MS patients facing walking challenges, offering them increased mobility and independence. Patients with MS disabilities rated between four and seven, indicating varying walking abilities, will be eligible for fampridine.
Trials have shown promising results, with 43% of patients experiencing improved walking speed and endurance. Aysen Slack, who previously self-funded fampridine, emphasized the positive impact the drug had on her mobility, expressing a desire to access it through the NHS.
Ensuring equitable access to fampridine across England is crucial, as highlighted by Ceri Smith, who stressed the importance of MS services facilitating its availability to all potential beneficiaries.